Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2025-06-02 00:00:00 ET · period of report 2025-05-29 · accession 0001415889-25-015270 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-02 | 2025-05-29 | ACAD | Brege Laura | Dir | M - OptEx | — | +9,387 | 29.5K | +47% | — |
| DM | 2025-06-02 | 2025-05-29 | ACAD | Brege Laura | Dir | A - Grant | $0.00 | +21.9K | 13.8K | New | $0 |
| D | 2025-06-02 | 2025-05-29 | ACAD | Brege Laura | Dir | M - OptEx | $0.00 | -9,387 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-29 | M | A | 9,387 | — | 29,541 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| 2 | Derivative | Restricted Stock Units | 2025-05-29 | A | A | 8,107 | $0.00 | 8,107 | D | — · — to — | 8,107 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F4) The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
| 3 | Derivative | Restricted Stock Units | 2025-05-29 | M | D | 9,387 | $0.00 | 0 | D | — · — to — | 9,387 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F2) The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. |
| 4 | Derivative | Director Stock Options (Right to Buy) | 2025-05-29 | A | A | 13,793 | $0.00 | 13,793 | D | $22.29 · — to 2035-05-28 | 13,793 Common Stock | (F3) The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |